Medullary Thyroid Carcinoma (MTC)


medullary thyroid cancer

Survivors Group Connects MTC Patients as New Therapies Offer Hope

In late February 2016, while getting dressed for work, George Labonte — the deputy police chief of Wrentham, Massachusetts — noticed a lump under his Adam’s apple as he knotted the tie of his uniform. Labonte’s primary care provider ordered imaging and referred the 35-year-old to an ear, nose, and throat specialist. A biopsy showed…
NORD t-shirts for sale

NORD Recognizes Progress in Fight Against Rare Disease With 2021 Rare Impact Awards

Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses. The virtual ceremony was hosted by John Whyte, MD, MPH, chief medical officer at WebMD, with commentary…

Patient Perspectives

MTC Clinical Insights

Medullary Thyroid Cancer Diagnosis Scan

Limitations of MTC Tumor Markers and Perspectives on Liquid Biopsy

Medullary thyroid carcinoma (MTC) presents with non-specific symptoms and diagnostic findings, which hampers its successful clinical management. Therefore, although rare, MTC accounts for 15% of all thyroid cancer-related deaths. Despite the efforts, the scientific community still faces the mirage of early MTC diagnosis. Family history and genetic testing are prime starting steps in MTC diagnostic…
MTC comorbidities

The Impact of Age on Sporadic MTC Prognosis

When it comes to rare cancers like medullary thyroid carcinoma (MTC), prognostic indicators often dictate treatment decisions and are therefore incredibly valuable. A study published in Cancers sought to establish the impact of advanced age on the clinical presentation and outcome of sporadic MTC. MTC comes in either sporadic or hereditary form (the sporadic being…